nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—chronic obstructive pulmonary disease	0.477	1	CbGaD
Palonosetron—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0522	0.15	CbGbCtD
Palonosetron—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0506	0.145	CbGbCtD
Palonosetron—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0506	0.145	CbGbCtD
Palonosetron—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0451	0.129	CbGbCtD
Palonosetron—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0424	0.122	CbGbCtD
Palonosetron—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0287	0.0821	CbGbCtD
Palonosetron—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0274	0.0783	CbGbCtD
Palonosetron—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0244	0.0698	CbGbCtD
Palonosetron—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0143	0.041	CbGbCtD
Palonosetron—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0135	0.0387	CbGbCtD
Palonosetron—Praziquantel—CYP1A2—chronic obstructive pulmonary disease	0.00345	1	CrCbGaD
Palonosetron—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00153	0.0667	CbGpPWpGaD
Palonosetron—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00134	0.0582	CbGpPWpGaD
Palonosetron—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00118	0.0515	CbGpPWpGaD
Palonosetron—HTR3A—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00115	0.0498	CbGpPWpGaD
Palonosetron—HTR3A—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.00102	0.0444	CbGpPWpGaD
Palonosetron—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000967	0.0421	CbGpPWpGaD
Palonosetron—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000491	0.0214	CbGpPWpGaD
Palonosetron—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000488	0.0212	CbGpPWpGaD
Palonosetron—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000416	0.0181	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000399	0.0173	CbGpPWpGaD
Palonosetron—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000388	0.0169	CbGpPWpGaD
Palonosetron—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000378	0.0165	CbGpPWpGaD
Palonosetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000376	0.0164	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000355	0.0155	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000345	0.015	CbGpPWpGaD
Palonosetron—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000333	0.00226	CcSEcCtD
Palonosetron—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000333	0.00226	CcSEcCtD
Palonosetron—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000333	0.00226	CcSEcCtD
Palonosetron—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.00225	CcSEcCtD
Palonosetron—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.00033	0.00224	CcSEcCtD
Palonosetron—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00224	CcSEcCtD
Palonosetron—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000325	0.00221	CcSEcCtD
Palonosetron—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000324	0.0141	CbGpPWpGaD
Palonosetron—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.0022	CcSEcCtD
Palonosetron—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00218	CcSEcCtD
Palonosetron—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000321	0.00218	CcSEcCtD
Palonosetron—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000317	0.00215	CcSEcCtD
Palonosetron—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00215	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000316	0.00215	CcSEcCtD
Palonosetron—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.00214	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000313	0.00213	CcSEcCtD
Palonosetron—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000312	0.0136	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000311	0.0135	CbGpPWpGaD
Palonosetron—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000311	0.00211	CcSEcCtD
Palonosetron—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000309	0.0021	CcSEcCtD
Palonosetron—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00208	CcSEcCtD
Palonosetron—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000303	0.00206	CcSEcCtD
Palonosetron—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000298	0.00203	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000297	0.00202	CcSEcCtD
Palonosetron—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000294	0.002	CcSEcCtD
Palonosetron—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00199	CcSEcCtD
Palonosetron—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00199	CcSEcCtD
Palonosetron—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000292	0.0127	CbGpPWpGaD
Palonosetron—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000291	0.00197	CcSEcCtD
Palonosetron—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00197	CcSEcCtD
Palonosetron—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00197	CcSEcCtD
Palonosetron—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00197	CcSEcCtD
Palonosetron—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00197	CcSEcCtD
Palonosetron—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000289	0.00196	CcSEcCtD
Palonosetron—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000289	0.00196	CcSEcCtD
Palonosetron—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.00196	CcSEcCtD
Palonosetron—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000288	0.00196	CcSEcCtD
Palonosetron—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000288	0.00196	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00195	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00195	CcSEcCtD
Palonosetron—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00194	CcSEcCtD
Palonosetron—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00194	CcSEcCtD
Palonosetron—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000284	0.00193	CcSEcCtD
Palonosetron—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000284	0.00193	CcSEcCtD
Palonosetron—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000283	0.00192	CcSEcCtD
Palonosetron—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000283	0.00192	CcSEcCtD
Palonosetron—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000283	0.00192	CcSEcCtD
Palonosetron—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000282	0.0123	CbGpPWpGaD
Palonosetron—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000282	0.0123	CbGpPWpGaD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00191	CcSEcCtD
Palonosetron—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000281	0.00191	CcSEcCtD
Palonosetron—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00189	CcSEcCtD
Palonosetron—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00189	CcSEcCtD
Palonosetron—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00188	CcSEcCtD
Palonosetron—Infection—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00187	CcSEcCtD
Palonosetron—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00187	CcSEcCtD
Palonosetron—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00186	CcSEcCtD
Palonosetron—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00186	CcSEcCtD
Palonosetron—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00185	CcSEcCtD
Palonosetron—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00185	CcSEcCtD
Palonosetron—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00185	CcSEcCtD
Palonosetron—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000272	0.00185	CcSEcCtD
Palonosetron—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000272	0.00185	CcSEcCtD
Palonosetron—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00184	CcSEcCtD
Palonosetron—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00184	CcSEcCtD
Palonosetron—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.00184	CcSEcCtD
Palonosetron—Infection—Montelukast—chronic obstructive pulmonary disease	0.00027	0.00183	CcSEcCtD
Palonosetron—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00183	CcSEcCtD
Palonosetron—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00183	CcSEcCtD
Palonosetron—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000269	0.00183	CcSEcCtD
Palonosetron—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00182	CcSEcCtD
Palonosetron—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000267	0.00181	CcSEcCtD
Palonosetron—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000266	0.00181	CcSEcCtD
Palonosetron—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00179	CcSEcCtD
Palonosetron—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000263	0.00179	CcSEcCtD
Palonosetron—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.00178	CcSEcCtD
Palonosetron—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00177	CcSEcCtD
Palonosetron—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00176	CcSEcCtD
Palonosetron—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00176	CcSEcCtD
Palonosetron—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000258	0.00175	CcSEcCtD
Palonosetron—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00175	CcSEcCtD
Palonosetron—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.00175	CcSEcCtD
Palonosetron—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00174	CcSEcCtD
Palonosetron—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00173	CcSEcCtD
Palonosetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000253	0.011	CbGpPWpGaD
Palonosetron—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000253	0.00172	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00172	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00172	CcSEcCtD
Palonosetron—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000251	0.00171	CcSEcCtD
Palonosetron—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.00171	CcSEcCtD
Palonosetron—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.0017	CcSEcCtD
Palonosetron—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00025	0.0017	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000248	0.00168	CcSEcCtD
Palonosetron—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00168	CcSEcCtD
Palonosetron—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00168	CcSEcCtD
Palonosetron—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00168	CcSEcCtD
Palonosetron—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00168	CcSEcCtD
Palonosetron—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000246	0.00167	CcSEcCtD
Palonosetron—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00166	CcSEcCtD
Palonosetron—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000244	0.00166	CcSEcCtD
Palonosetron—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000244	0.00166	CcSEcCtD
Palonosetron—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00166	CcSEcCtD
Palonosetron—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.00165	CcSEcCtD
Palonosetron—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000242	0.00164	CcSEcCtD
Palonosetron—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000241	0.00164	CcSEcCtD
Palonosetron—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000241	0.0105	CbGpPWpGaD
Palonosetron—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00163	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00163	CcSEcCtD
Palonosetron—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000239	0.00163	CcSEcCtD
Palonosetron—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000239	0.00163	CcSEcCtD
Palonosetron—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.00163	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00162	CcSEcCtD
Palonosetron—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000239	0.0104	CbGpPWpGaD
Palonosetron—Pain—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Palonosetron—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Palonosetron—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Palonosetron—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Palonosetron—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.00161	CcSEcCtD
Palonosetron—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000236	0.0103	CbGpPWpGaD
Palonosetron—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.0016	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000235	0.00159	CcSEcCtD
Palonosetron—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000234	0.00159	CcSEcCtD
Palonosetron—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00159	CcSEcCtD
Palonosetron—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00158	CcSEcCtD
Palonosetron—Pain—Montelukast—chronic obstructive pulmonary disease	0.000233	0.00158	CcSEcCtD
Palonosetron—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000232	0.00158	CcSEcCtD
Palonosetron—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000231	0.00157	CcSEcCtD
Palonosetron—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000231	0.01	CbGpPWpGaD
Palonosetron—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00023	0.00156	CcSEcCtD
Palonosetron—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00023	0.00156	CcSEcCtD
Palonosetron—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000229	0.00997	CbGpPWpGaD
Palonosetron—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000229	0.00155	CcSEcCtD
Palonosetron—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.00155	CcSEcCtD
Palonosetron—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.00155	CcSEcCtD
Palonosetron—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00154	CcSEcCtD
Palonosetron—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00154	CcSEcCtD
Palonosetron—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000227	0.00986	CbGpPWpGaD
Palonosetron—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.00154	CcSEcCtD
Palonosetron—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.00154	CcSEcCtD
Palonosetron—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00152	CcSEcCtD
Palonosetron—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00152	CcSEcCtD
Palonosetron—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00151	CcSEcCtD
Palonosetron—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000221	0.00961	CbGpPWpGaD
Palonosetron—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00149	CcSEcCtD
Palonosetron—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00149	CcSEcCtD
Palonosetron—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00149	CcSEcCtD
Palonosetron—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00149	CcSEcCtD
Palonosetron—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.00149	CcSEcCtD
Palonosetron—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000217	0.00945	CbGpPWpGaD
Palonosetron—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000217	0.00147	CcSEcCtD
Palonosetron—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000217	0.00147	CcSEcCtD
Palonosetron—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000217	0.00147	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000216	0.00939	CbGpPWpGaD
Palonosetron—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00146	CcSEcCtD
Palonosetron—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000215	0.00146	CcSEcCtD
Palonosetron—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000215	0.00146	CcSEcCtD
Palonosetron—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000215	0.00146	CcSEcCtD
Palonosetron—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00146	CcSEcCtD
Palonosetron—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000212	0.00923	CbGpPWpGaD
Palonosetron—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00141	CcSEcCtD
Palonosetron—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00141	CcSEcCtD
Palonosetron—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00139	CcSEcCtD
Palonosetron—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00139	CcSEcCtD
Palonosetron—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00139	CcSEcCtD
Palonosetron—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000204	0.00887	CbGpPWpGaD
Palonosetron—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000202	0.00137	CcSEcCtD
Palonosetron—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.0002	0.00136	CcSEcCtD
Palonosetron—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.0002	0.00869	CbGpPWpGaD
Palonosetron—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000199	0.00135	CcSEcCtD
Palonosetron—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.00135	CcSEcCtD
Palonosetron—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000196	0.00133	CcSEcCtD
Palonosetron—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.00133	CcSEcCtD
Palonosetron—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00133	CcSEcCtD
Palonosetron—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000193	0.00131	CcSEcCtD
Palonosetron—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00131	CcSEcCtD
Palonosetron—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00131	CcSEcCtD
Palonosetron—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000192	0.00835	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000191	0.00831	CbGpPWpGaD
Palonosetron—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00129	CcSEcCtD
Palonosetron—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00129	CcSEcCtD
Palonosetron—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000189	0.00128	CcSEcCtD
Palonosetron—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00128	CcSEcCtD
Palonosetron—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000187	0.00813	CbGpPWpGaD
Palonosetron—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00126	CcSEcCtD
Palonosetron—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00126	CcSEcCtD
Palonosetron—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.00125	CcSEcCtD
Palonosetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00801	CbGpPWpGaD
Palonosetron—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000184	0.00125	CcSEcCtD
Palonosetron—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000184	0.00125	CcSEcCtD
Palonosetron—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00018	0.00122	CcSEcCtD
Palonosetron—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00122	CcSEcCtD
Palonosetron—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000177	0.00769	CbGpPWpGaD
Palonosetron—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000177	0.0012	CcSEcCtD
Palonosetron—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.0012	CcSEcCtD
Palonosetron—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000175	0.00762	CbGpPWpGaD
Palonosetron—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00119	CcSEcCtD
Palonosetron—Rash—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00119	CcSEcCtD
Palonosetron—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.00119	CcSEcCtD
Palonosetron—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000175	0.00119	CcSEcCtD
Palonosetron—Headache—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00118	CcSEcCtD
Palonosetron—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00118	CcSEcCtD
Palonosetron—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Palonosetron—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00118	CcSEcCtD
Palonosetron—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00117	CcSEcCtD
Palonosetron—Rash—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00116	CcSEcCtD
Palonosetron—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00116	CcSEcCtD
Palonosetron—Headache—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00116	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000168	0.0073	CbGpPWpGaD
Palonosetron—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000168	0.00729	CbGpPWpGaD
Palonosetron—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00113	CcSEcCtD
Palonosetron—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00112	CcSEcCtD
Palonosetron—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00112	CcSEcCtD
Palonosetron—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00112	CcSEcCtD
Palonosetron—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00112	CcSEcCtD
Palonosetron—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00112	CcSEcCtD
Palonosetron—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000162	0.0011	CcSEcCtD
Palonosetron—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00108	CcSEcCtD
Palonosetron—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00108	CcSEcCtD
Palonosetron—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000158	0.00689	CbGpPWpGaD
Palonosetron—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00106	CcSEcCtD
Palonosetron—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000156	0.00106	CcSEcCtD
Palonosetron—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.00105	CcSEcCtD
Palonosetron—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000154	0.0067	CbGpPWpGaD
Palonosetron—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00103	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.00102	CcSEcCtD
Palonosetron—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.00645	CbGpPWpGaD
Palonosetron—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.00645	CbGpPWpGaD
Palonosetron—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.001	CcSEcCtD
Palonosetron—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000997	CcSEcCtD
Palonosetron—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000976	CcSEcCtD
Palonosetron—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000948	CcSEcCtD
Palonosetron—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000139	0.000943	CcSEcCtD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000139	0.00604	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000138	0.00599	CbGpPWpGaD
Palonosetron—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000933	CcSEcCtD
Palonosetron—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000924	CcSEcCtD
Palonosetron—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000923	CcSEcCtD
Palonosetron—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.000917	CcSEcCtD
Palonosetron—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000915	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000135	0.00586	CbGpPWpGaD
Palonosetron—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000909	CcSEcCtD
Palonosetron—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000909	CcSEcCtD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000133	0.00578	CbGpPWpGaD
Palonosetron—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000129	0.000873	CcSEcCtD
Palonosetron—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000124	0.00084	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000118	0.00513	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000117	0.00508	CbGpPWpGaD
Palonosetron—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000788	CcSEcCtD
Palonosetron—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000785	CcSEcCtD
Palonosetron—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000774	CcSEcCtD
Palonosetron—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000774	CcSEcCtD
Palonosetron—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000771	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000113	0.00493	CbGpPWpGaD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000769	CcSEcCtD
Palonosetron—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000765	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000752	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000742	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.00475	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.00474	CbGpPWpGaD
Palonosetron—Infection—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000737	CcSEcCtD
Palonosetron—Shock—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00073	CcSEcCtD
Palonosetron—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000728	CcSEcCtD
Palonosetron—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000724	CcSEcCtD
Palonosetron—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000721	CcSEcCtD
Palonosetron—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000707	CcSEcCtD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00446	CbGpPWpGaD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00446	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000103	0.00446	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000101	0.0044	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	9.99e-05	0.00435	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.95e-05	0.000676	CcSEcCtD
Palonosetron—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.94e-05	0.000675	CcSEcCtD
Palonosetron—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.88e-05	0.000671	CcSEcCtD
Palonosetron—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.81e-05	0.000666	CcSEcCtD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.79e-05	0.00426	CbGpPWpGaD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.66e-05	0.0042	CbGpPWpGaD
Palonosetron—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	9.62e-05	0.000653	CcSEcCtD
Palonosetron—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	9.59e-05	0.00417	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	9.58e-05	0.00417	CbGpPWpGaD
Palonosetron—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	9.5e-05	0.000645	CcSEcCtD
Palonosetron—Rash—Prednisolone—chronic obstructive pulmonary disease	9.48e-05	0.000644	CcSEcCtD
Palonosetron—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.47e-05	0.000643	CcSEcCtD
Palonosetron—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.42e-05	0.00064	CcSEcCtD
Palonosetron—Headache—Prednisolone—chronic obstructive pulmonary disease	9.42e-05	0.00064	CcSEcCtD
Palonosetron—Constipation—Prednisone—chronic obstructive pulmonary disease	9.34e-05	0.000635	CcSEcCtD
Palonosetron—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	9.01e-05	0.00392	CbGpPWpGaD
Palonosetron—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.93e-05	0.000607	CcSEcCtD
Palonosetron—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.93e-05	0.000607	CcSEcCtD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.8e-05	0.00383	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.69e-05	0.00378	CbGpPWpGaD
Palonosetron—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.64e-05	0.000587	CcSEcCtD
Palonosetron—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.64e-05	0.000587	CcSEcCtD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.29e-05	0.00361	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	8.21e-05	0.00357	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.18e-05	0.00356	CbGpPWpGaD
Palonosetron—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.05e-05	0.000547	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.93e-05	0.00345	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.91e-05	0.00344	CbGpPWpGaD
Palonosetron—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.84e-05	0.000532	CcSEcCtD
Palonosetron—HTR3A—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	7.82e-05	0.0034	CbGpPWpGaD
Palonosetron—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.73e-05	0.000525	CcSEcCtD
Palonosetron—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.47e-05	0.000508	CcSEcCtD
Palonosetron—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.22e-05	0.000491	CcSEcCtD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	7.14e-05	0.00311	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	7e-05	0.00305	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.98e-05	0.00304	CbGpPWpGaD
Palonosetron—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.95e-05	0.000472	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.9e-05	0.003	CbGpPWpGaD
Palonosetron—Rash—Prednisone—chronic obstructive pulmonary disease	6.89e-05	0.000468	CcSEcCtD
Palonosetron—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000467	CcSEcCtD
Palonosetron—Headache—Prednisone—chronic obstructive pulmonary disease	6.84e-05	0.000465	CcSEcCtD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.72e-05	0.00292	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	6.63e-05	0.00288	CbGpPWpGaD
Palonosetron—Nausea—Prednisone—chronic obstructive pulmonary disease	6.49e-05	0.000441	CcSEcCtD
Palonosetron—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	6.44e-05	0.0028	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.4e-05	0.00278	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.31e-05	0.00275	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.91e-05	0.00257	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.84e-05	0.00254	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.8e-05	0.00252	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.72e-05	0.00249	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	5.67e-05	0.00247	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.19e-05	0.00226	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.84e-05	0.0021	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.8e-05	0.00209	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.77e-05	0.00208	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.7e-05	0.00204	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.56e-05	0.00199	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.51e-05	0.00196	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.44e-05	0.00193	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.41e-05	0.00192	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.38e-05	0.00191	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.32e-05	0.00188	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.32e-05	0.00188	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.21e-05	0.00183	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.16e-05	0.00181	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.16e-05	0.00181	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.12e-05	0.00179	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.12e-05	0.00179	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.1e-05	0.00178	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.04e-05	0.00176	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.79e-05	0.00165	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.77e-05	0.00164	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.74e-05	0.00163	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.71e-05	0.00162	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.57e-05	0.00155	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.52e-05	0.00153	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.39e-05	0.00148	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.16e-05	0.00138	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.12e-05	0.00136	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.91e-05	0.00126	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.87e-05	0.00125	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.87e-05	0.00125	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.75e-05	0.0012	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.72e-05	0.00118	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.25e-05	0.000977	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.22e-05	0.000964	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.18e-05	0.000951	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.05e-05	0.000891	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.03e-05	0.000884	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.9e-05	0.000828	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.85e-05	0.000805	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.72e-05	0.000749	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.47e-05	0.000639	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.43e-05	0.000621	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.37e-05	0.000596	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.33e-05	0.000578	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.19e-05	0.000519	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.18e-05	0.000513	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.08e-05	0.000468	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.01e-05	0.00044	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.99e-06	0.000435	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.92e-06	0.000432	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.32e-06	0.000405	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.12e-06	0.000397	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.27e-06	0.00036	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.16e-06	0.000355	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.8e-06	0.00034	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	7.71e-06	0.000336	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.6e-06	0.000331	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.21e-06	0.000314	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.04e-06	0.000306	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.01e-06	0.000305	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.91e-06	0.000301	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.48e-06	0.000282	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.44e-06	0.00028	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.1e-06	0.000266	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.41e-06	0.000235	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.33e-06	0.000232	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.97e-06	0.000216	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.9e-06	0.000213	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.71e-06	0.000205	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.69e-06	0.000204	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.15e-06	0.000181	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.97e-06	0.000173	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.2e-06	0.000139	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.06e-06	0.000133	CbGpPWpGaD
